Chemotherapeutics of visceral leishmaniasis: present and future developments.

about

Leishmaniasis: current challenges and prospects for elimination with special focus on the South Asian region.

P2860

Q52593359-C33D68AA-4E66-4B3C-B435-015D17758BCF

P2860

Chemotherapeutics of visceral leishmaniasis: present and future developments.

Item

http://www.wikidata.org/entity/Q46713325

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Chemotherapeutics of visceral leishmaniasis: present and future developments.

@en

Chemotherapeutics of visceral leishmaniasis: present and future developments.

@nl

type

Item

label

Chemotherapeutics of visceral leishmaniasis: present and future developments.

@en

Chemotherapeutics of visceral leishmaniasis: present and future developments.

@nl

prefLabel

Chemotherapeutics of visceral leishmaniasis: present and future developments.

@en

Chemotherapeutics of visceral leishmaniasis: present and future developments.

@nl

P1476

Chemotherapeutics of visceral leishmaniasis: present and future developments.

@en

P2093

Anup Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Leishmaniasis worldwide and global estimates of its incidence

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial

Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani

Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1017/S0031182017002116

http://www.w3.org/2001/XMLSchema#string

P50

Shyam Sundar

P577

2017-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29215329

http://www.w3.org/2001/XMLSchema#string

P921

visceral leishmaniasis

chemotherapy

P932

5984184

http://www.w3.org/2001/XMLSchema#string

Chemotherapeutics of visceral leishmaniasis: present and future developments.

about

P2860

P2860

Chemotherapeutics of visceral leishmaniasis: present and future developments.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P50

P577

P698

P921

P932